Phospholipase A2 sensitive liposomes for delivery of small interfering RNA (siRNA).
Small interfering RNA (siRNA) is potent and highly specific for gene silencing and there is currently a lot of enthusiasm for developing siRNA into a drug. However, for most therapeutic applications of siRNA, delivery systems are needed. These delivery systems have multiple requirements and should on one hand ideally be stable carriers protecting the siRNA from degradation and on the other hand assist the siRNA in overcoming membrane barriers for intracellular delivery to the cytosol. Long-circulating liposomes, which are sensitive to secretory phospholipase A(2) (sPLA(2)) are feasible delivery systems for systemic administration of drugs due to their passive targeting to pathological tissue via the enhanced permeability and retention (EPR) effect and their site-specific, enzyme-triggered release of encapsulated drug in response to sPLA(2) which exists locally at elevated levels at, e.g,. sites of inflammation. However, recent data suggest that endosomal membrane destabilizing approaches could be addressed to design sPLA(2)-sensitive liposomes as successful delivery systems for siRNA to the RNA interference pathway in the cytoplasm upon systemic administration.
Foged
Camilla
C
Department of Pharmaceutics and Analytical Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Copenhagen, Denmark. cfo@farma.ku.dk
Nielsen
Hanne M
HM
Frokjaer
Sven
S
D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D006801:Humans; D008081:Liposomes; D010539:Permeability; D054467:Phospholipases A2 / Q000737:chemistry*; D034622:RNA Interference; D034741:RNA, Small Interfering
D008081:Liposomes; D034741:RNA, Small Interfering; D054467:Phospholipases A2